I think it's going to be an interesting fight. By the standards the drug companies want to use, at least 1/3 of the US population might be diagnostically suit

I think it's going to be an interesting fight. By the standards the drug companies want to use, at least 1/3 of the US population might be diagnostically suited for a GIP prescription, which, as current understood, they would have to take every month for the rest of their lives. At $1000/month, treating half that cohort would add 15% to the US health care bill. That ain't gonna happen without a fight.